Loba biotech GmbH, a wholly owned GMP manufacturing subsidiary of pharmaand GmbH (pharma&), has chosen Generis’ CARA Life Sciences Platform to launch its digital Quality Management System (QMS). The initial phase will focus on digitalizing Standard Operating Procedures (SOPs) and implementing the training module, with a go-live target set for Q3 2025. This strategic move aims to ensure future compliance and operational efficiency by digitizing critical quality processes. CARA offers a comprehensive suite of tools for managing Quality Documents, Training, Quality Events, and more. Its scalable solution supports Loba biotech GmbH’s growth and commitment to excellence .
Max Kelleher, CEO at Generis, expressed excitement about supporting Loba biotech GmbH in their digital transformation journey, highlighting CARA’s robust features and user-friendly interface.
About Generis
Generis is a UK-headquartered developer of world-class data, content and business process management for regulated industries globally. 60% of the top 20 life sciences companies rely on Generis’ flagship CARA™ Life Sciences Platform, including AbbVie, UCB, Biogen, Reckitt, Bristol Myers Squibb, Bayer, Pfizer, and Merck KGaA. Today Generis serves more than 750,000 users worldwide, across use cases ranging from RIM, Regulatory / R&D and Safety to Clinical, Non-clinical, Quality GxP, CMC, Pharmacovigilance, Medical Information / Medical Affairs applications and more. More at www.caralifesciences.com
